evaluated tolerance single dose cgy delivered electron beam linear accelerator tumour bed patients breast cancer undergoing conservative treatment instead traditional boost enrolled NUMBER patients cn0 NUMBER received dose NUMBER cgy NUMBER NUMBER cgy NUMBER NUMBER cgy NUMBER NUMBER cgy external beam radiation therapy ebrt conventional schedule NUMBER cgy total dose performed wound healing median gap ioert ebrt NUMBER weeks patients adverse prognostic factors undergoing chemotherapy including doxorubicin taxanes received ebrt completion chemotherapy patient prosthesis implant yielding surgical scar NUMBER months ioert NUMBER cycles doxorubicin NUMBER cycles cmf complicated frequent mastitis patient large serum collection axilla manifested delayed scar formation significant increase healing time morbidity observed NUMBER patients developed mastitis cosmetic outcome good patients treatment tolerated ioert doses delivered date local relapses NUMBER NUMBER ioert dedicated ct1 NUMBER surgery related follow NUMBER NUMBER